Confirm the clinical SPSD phenotype before treating an antibody result
Classic SPS typically causes progressive axial and proximal-limb stiffness with painful spasms triggered by touch, sudden noise, movement or emotional stress. Stiff-limb syndrome can remain focal, while PERM adds brainstem, autonomic or myoclonic features and can be clinically severe. Many other neurological, orthopedic, pain and functional disorders can mimic parts of this picture, so the diagnosis should be made from the complete syndrome rather than laboratory testing alone.
GAD65 is common, but antibody context matters
Orphanet describes GAD antibodies in a large proportion of SPSD, but other clinically important antibodies include glycine-receptor and amphiphysin antibodies. High-titer or intrathecal GAD65 findings are more informative than a low isolated serum result, particularly because GAD antibodies can occur in type 1 diabetes and other autoimmune settings. The laboratory result should therefore be interpreted with phenotype, CSF when relevant and neurophysiology.
Neurophysiology can provide objective support
Heidelberg's electrophysiology SOP describes persistent motor-unit activity in stiff muscles and generalized reflex spasms or co-contraction patterns as supportive findings. Specialized EMG/reflex testing is especially useful when symptoms are atypical, antibody testing is negative or the differential includes dystonia, spasticity, functional neurological disorder or another hyperexcitability syndrome.
PERM and glycine-receptor disease need urgent specialist assessment
PERM can include rapidly progressive stiffness, myoclonus, exaggerated startle, bulbar dysfunction, autonomic instability or encephalopathic features. Glycine-receptor antibodies are particularly associated with parts of this spectrum. Rapid progression, new swallowing or breathing difficulty, severe autonomic symptoms, repeated falls or reduced consciousness should be assessed urgently where the patient is located rather than delayed for planned international travel.
Paraneoplastic SPSD requires active tumor evaluation
Amphiphysin-associated SPSD and some other antibody patterns can be paraneoplastic. Orphanet describes associations with breast, lung, colon and thymic tumors. The appropriate cancer search depends on age, sex, smoking history, antibody profile and clinical phenotype and can include targeted CT, PET/CT, mammography or other oncology-directed testing. Treating an identified malignancy is central to the paraneoplastic pathway.
Symptomatic therapy targets stiffness and painful spasms
Benzodiazepines and baclofen are standard symptomatic options in SPSD and can reduce stiffness and stimulus-sensitive spasms. Other agents may be used according to symptoms and tolerance. Sedation, falls, respiratory risk and medication interactions matter, so dose escalation should be supervised rather than copied from online protocols.
IVIG has the strongest established immunotherapy evidence
For patients with a convincing autoimmune SPSD phenotype and clinically important disability, IVIG is the immunotherapy with the clearest controlled-trial support. Response should be judged with objective functional goals such as walking, spasm burden, falls and medication requirement rather than antibody titre alone. Long-term dosing and continuation depend on demonstrated benefit and safety.
Other immunotherapies are selected rather than automatic
Steroids, plasma exchange, rituximab and other immunosuppressive strategies are used in selected refractory, rapidly progressive, antibody-defined or paraneoplastic cases, but evidence strength varies by SPSD subtype and treatment. Freiburg's Neuroimmunboard explicitly reviews therapy escalation in rare neuroimmunological disease including stiff-person syndrome. Experimental cell-based or highly intensive immune therapies should be distinguished clearly from established routine care.
Rehabilitation should account for startle, spasms and fall risk
Physiotherapy and occupational therapy can support mobility, flexibility, safe transfers and confidence, but aggressive stretching or sudden external stimuli can provoke spasms in some patients. Rehabilitation should therefore be individualized and coordinated with medication control of stiffness and anxiety-related triggering rather than delivered as a generic strengthening program.
Associated autoimmunity can add useful diagnostic context
SPSD can coexist with type 1 diabetes, autoimmune thyroid disease, pernicious anemia and other autoimmune disorders. These associations can support the broader autoimmune context but do not prove the neurological diagnosis. A specialist may review glucose, thyroid, B12 and other targeted studies according to history and antibody findings.
What to send for a German SPSD second opinion
Send enough original data for the center to decide whether the syndrome and antibody findings really fit SPSD before planning treatment or travel.
- Neurology and neuroimmunology reports describing stiffness, spasms, triggers, falls and progression
- Complete GAD65, glycine-receptor, amphiphysin and other neuronal-antibody results with assay and titre where reported
- Serum and CSF reports if lumbar puncture was performed
- Needle EMG, reflex-polygraphy or other neurophysiology reports
- Brain/spinal MRI and other tests used to exclude structural or inflammatory mimics
- Cancer-screening imaging and oncology history where relevant
- Current benzodiazepine, baclofen and other symptomatic medication with response/side effects
- Previous IVIG, steroids, plasma exchange, rituximab or other immunotherapy with objective response
- Current walking aids, fall history and rehabilitation plan
- A specific question: confirm SPSD, interpret antibodies, review immunotherapy, assess tumor search or plan rehabilitation
Official sources
Sources last checked 2026-09-02. Clinical pathways, eligibility and hospital procedures can change; confirm current requirements directly with the treating center.
- Stiff person spectrum disorder — Orphanet ↗
- Rare neurological diseases center – Stiff-Person syndrome — Heidelberg University Hospital ↗
- Heidelberg electrophysiology SOP – Stiff-Person syndrome — Heidelberg University Hospital ↗
- Neurological movement disorders — Heidelberg University Hospital ↗
- Freiburg Neuroimmunboard — University Medical Center Freiburg ↗